论文部分内容阅读
目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织miR-10b的表达及其与临床病理因素的关系。方法:收集2005-01-01-2006-12-01中国医科大学附属第一医院病理科存档蜡块50例NSCLC和癌旁肺组织(距离癌组织>3cm),采用实时定量PCR检测NSCLC组织和相应癌旁组织中miR-10b的表达,分析miR-10b表达与临床病理参数的相关性,通过Kaplan-Meier进行生存分析。结果:50例NSCLC组织和相应癌旁组织中,34例癌组织miR-10b表达高于癌旁组织;癌组织miR-10b表达为1.55±0.57,相应癌旁组织为1.01±0.38,t=-2.182,P=0.034。miR-10b的表达水平与病理分期(U=189,P=0.010)和淋巴结转移(χ2=6.650,P=0.010)呈正相关,而与其他临床病理因素如性别、年龄、发病部位、病理分型和分化等均无相关性。miR-10b高表达的NSCLC患者5年生存率为4%(1/25),明显低于miR-10b低表达患者的32%(8/25),χ2=6.504,P=0.011。结论:miR-10b在NSCLC的发生发展中起着重要作用,可能成为NSCLC预后判断的指标,miRNA可能成为NSCLC分子诊断和靶向治疗的重要指标。
Objective: To investigate the expression of miR-10b in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological factors. Methods: Fifty NSCLC and adjacent non-cancerous lung tissues (> 3cm away from the cancer tissue) were collected from Department of Pathology, the First Affiliated Hospital of China Medical University from January 2005 to January 2006. The real- The relative expression of miR-10b in paracancerous tissues was analyzed. The correlation between miR-10b expression and clinicopathological parameters was analyzed. Survival analysis was performed by Kaplan-Meier. Results: The expression of miR-10b in 34 cases of NSCLC tissues and corresponding paracancerous tissues was higher than that of paracancerous tissues; the expression of miR-10b in cancer tissues was 1.55 ± 0.57, corresponding paracancerous tissues were 1.01 ± 0.38, t = - 2.182, P = 0.034. The expression of miR-10b was positively correlated with pathological stage (U = 189, P = 0.010) and lymph node metastasis (χ2 = 6.650, P = 0.010), but not with other clinical and pathological factors such as gender, age, No correlation with differentiation and so on. The 5-year survival rate of NSCLC patients with miR-10b overexpression was 4% (1/25), significantly lower than 32% (8/25) patients with low miR-10b expression, χ2 = 6.504, P = 0.011. Conclusion: miR-10b plays an important role in the occurrence and development of NSCLC and may be used as an indicator of prognosis in NSCLC. MiRNA may be an important marker for molecular diagnosis and targeted therapy of NSCLC.